Group One Trading’s Cidara Therapeutics CDTX Stock Holding History

Group One Trading’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-31,300	Closed	-$6.91M	–	7732
2025 Q4	$6.91M	Sell	31,300 -2,100	-6%	-$339K	0.01%	1222
2025 Q3	$3.2M	Buy	33,400 +25,400	+318%	+$1.62M	0.01%	1886
2025 Q2	$390K	Buy	+8,000	New	+$192K	﹤0.01%	3678
2023 Q2	–	Sell	-55	Closed	-$1.4K	–	7687
2023 Q1	$1.4K	Buy	+55	New	+$1.56K	﹤0.01%	6700
2022 Q4	–	Sell	-50	Closed	-$1K	–	7300
2022 Q3	$1K	Buy	+50	New	+$690	﹤0.01%	7278
2021 Q3	–	Sell	-500	Closed	-$20K	–	8203
2021 Q2	$20K	Buy	+500	New	+$21.2K	﹤0.01%	7176
2018 Q2	–	Sell	-55	Closed	-$4K	–	5116
2018 Q1	$4K	Buy	+55	New	+$7.51K	﹤0.01%	4542

Group One Trading's CDTX Position: Q4 2025 in Review

Group One Trading sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 21,403 shares — an estimated $3.46M sold.

Group One Trading first reported a position in CDTX in Q1 2018 and held it in 15 quarters. The position peaked at $2.05M in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

Group One Trading reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
Group One Trading sold 21,403 Cidara Therapeutics shares in Q4 2025, an estimated $3.46M.
Group One Trading first reported a position in Cidara Therapeutics in Q1 2018 and held it in 15 quarters.
Group One Trading's Cidara Therapeutics position peaked at $2.05M in Q3 2025.
255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.